Skip to main content
    U

    Uniqure NV (QURE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.88
    -1.93 (-8.11%)

    Market Cap: $1.67B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Uniqure NV (QURE) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Uniqure NV are Ultragenyx (RARE), Pharvaris BV (PHVS) and Nurix Therapeutics (NRIX). By market cap, Uniqure NV ranks 6th of the 13 companies on this page; Pharvaris BV (PHVS) is the largest at $2.36B. The median P/E of the 4 companies with a P/E is 27.3x.

    Peer Comparison

    QURE's ROIC of -57.9% is below the peer median of -34.4%, and its revenue growth of 40.4% is above the median of 11.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Uniqure NV (QURE)$1.67BN/A75.8x0.0%-57.9%40.4%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Pharvaris BV (PHVS)$2.36BN/AN/A0.0%N/A0.0%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Nuvation Bio Inc (NUVB)$1.41BN/A6.7x-67.4%-18.7%242.6%0.00%
    CureVac NV (CVAC)$1.05BN/A1.8x182.1%N/A-89.0%0.00%
    Pharming Group NV (PHAR)$891.80M39.3x2.4x6.3%7.9%20.8%0.00%
    Aurinia Pharmaceuticals Inc (AUPH)$2.11B15.2x6.4x97.7%N/A13.9%0.00%
    UroGen Pharma Ltd (URGN)$1.28BN/A5.7x-26.3%-73.7%223.9%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    Trevi Therapeutics Inc (TRVI)$1.95BN/AN/A0.0%N/A0.0%0.00%
    Precigen Inc (PGEN)$1.63B98.6x9.9x15.5%18.9%2438.0%0.00%
    Intellia Therapeutics Inc (NTLA)$1.36BN/A26.1x0.0%-50.0%-48.0%0.00%
    Peer median$1.63B27.3x6.0x0.0%-34.4%11.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Uniqure NV, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    Pharvaris BV (PHVS)
    Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies.
    PHVS competitors
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Nuvation Bio Inc (NUVB)
    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology.
    NUVB competitors
    CureVac NV (CVAC)
    CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA).
    Pharming Group NV (PHAR)
    Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States...
    PHAR competitors
    Aurinia Pharmaceuticals Inc (AUPH)
    Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China.
    AUPH competitors
    UroGen Pharma Ltd (URGN)
    UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases...
    URGN competitors
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors
    Trevi Therapeutics Inc (TRVI)
    Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious...
    TRVI competitors
    Precigen Inc (PGEN)
    Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
    PGEN competitors
    Intellia Therapeutics Inc (NTLA)
    Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
    NTLA competitors

    Frequently Asked Questions About QURE

    Who are Uniqure NV's main competitors?

    The companies most similar to Uniqure NV include Ultragenyx (RARE), Pharvaris BV (PHVS), Nurix Therapeutics (NRIX), Nuvation Bio (NUVB) and CureVac NV (CVAC), listed from the closest match.

    Who is Uniqure NV's biggest competitor?

    Pharvaris BV (PHVS) is the largest of the similar companies at $2.36B; Ultragenyx (RARE) is the closest match by business profile, size, sector and industry.

    How does QURE stock compare with its competitors?

    QURE's P/S is 75.8x against a peer median of 6.0x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Uniqure NV's competitors pays a higher dividend?

    Uniqure NV pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Uniqure NV bigger than its competitors?

    No. Uniqure NV is 6th by market cap among the 13 companies on this page; the largest is Pharvaris BV (PHVS) at $2.36B.